We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Diabetes therapeutics such as glucose and weight control are major physiological functions of the new glucagon-like peptide-1 (GLP-1) agonists. But is there evidence to suggest that GLP-1 may also have some cardiovascular benefits? Join host Dr. Steven Edelman and Dr. John Buse, professor of medicine at the University of North Carolina at Chapel Hill School of Medicine, as they discuss the emerging cardiovascular actions of incretin hormones.
Stay current with the best on medical education
